Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice

Virology

Volumn 468-470, Issue , 2014, Pages 28-35

  Tretyakova, Irina ^a   Nickols, Brian ^a   Hidajat, Rachmat ^a   Jokinen, Jenny ^b   Lukashevich, Igor S ^b   Pushko, Peter ^a  

^a Medigen Inc   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

17D vaccine; DNA vaccine; Flavivirus; Live attenuated vaccine; Yellow fever virus; YFV

Indexed keywords

DNA VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; VIRUS RNA; YELLOW FEVER VACCINE; LIVE VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA IMMUNIZATION; DRUG DESIGN; DRUG SAFETY; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; SEROCONVERSION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHLOROCEBUS AETHIOPS; GENETICS; IMMUNOLOGY; VERO CELL LINE; YELLOW FEVER VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINES, ATTENUATED; VACCINES, DNA; VERO CELLS; VIRAL VACCINES; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84906056807     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.07.050     Document Type: Article

References (50)

1. Barban V., Girerd Y., Aguirre M., Gulia S., Petiard F., Riou P., Barrere B., Lang J. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 2007, 25:2941-2950.
2. Beck A., Guzman H., Li L., Ellis B., Tesh R.B., Barrett A.D. Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into east and west Africa. PLoS Negl. Trop. Dis. 2013, 7:e1910.
3. Beck A., Tesh R.B., Wood T.G., Widen S.G., Ryman K.D., Barrett A.D. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. J. Infect. Dis. 2014, 209:334-344.
4. Bredenbeek P.J., Kooi E.A., Lindenbach B., Huijkman N., Rice C.M., Spaan W.J. A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J. Gen. Virol. 2003, 84:1261-1268.
5. Bredenbeek P.J., Molenkamp R., Spaan W.J., Deubel V., Marianneau P., Salvato M.S., Moshkoff D., Zapata J., Tikhonov I., Patterson J., Carrion R., Ticer A., Brasky K., Lukashevich I.S. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006, 345:299-304.
6. Breugelmans J.G., Lewis R.F., Agbenu E., Veit O., Jackson D., Domingo C., Bothe M., Perea W., Niedrig M., Gessner B.D., Yactayo S., group Y.A. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 2013, 31:1819-1829.
7. Cottin P., Niedrig M., Domingo C. Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review. Expert Rev. Vaccines 2013, 12:1351-1368.
8. dos Santos C.N., Post P.R., Carvalho R., Ferreira, Rice C.M., Galler R. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res. 1995, 35:35-41.
9. Garske T., Van Kerkhove M.D., Yactayo S., Ronveaux O., Lewis R.F., Staples J.E., Perea W., Ferguson N.M., Yellow Fever Expert C. Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014, 11:e1001638.
10. Gotuzzo E., Yactayo S., Cordova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am. J. Trop. Med. Hyg. 2013, 89:434-444.
11. Grard G., Moureau G., Charrel R.N., Holmes E.C., Gould E.A., de Lamballerie X. Genomics and evolution of Aedes-borne flaviviruses. J. Gen. Virol. 2010, 91:87-94.
12. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
13. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
14. Heinz F.X., Stiasny K. Flaviviruses and their antigenic structure. J. Clin. Virol. 2012, 55:289-295.
15. Ishikawa T., Yamanaka A., Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 2014, 32:1326-1337.
16. Jennings A.D., Whitby J.E., Minor P.D., Barrett A.D. Comparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses. Vaccine 1993, 11:679-681.
17. Jentes E.S., Poumerol G., Gershman M.D., Hill D.R., Lemarchand J., Lewis R.F., Staples J.E., Tomori O., Wilder-Smith A., Monath T.P., Informal W.H.O.W.G.o.G.R.f.Y.F. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO working group on geographic risk for Yellow Fever. Lancet Infect. Dis. 2011, 11:622-632.
18. Julander J.G. Experimental therapies for yellow fever. Antivir. Res. 2013, 97:169-179.
19. Khromykh A.A., Meka H., Guyatt K.J., Westaway E.G. Essential role of cyclization sequences in flavivirus RNA replication. J. Virol. 2001, 75:6719-6728.
20. Lang J., Zuckerman J., Clarke P., Barrett P., Kirkpatrick C., Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am. J. Trop. Med. Hyg. 1999, 60:1045-1050.
21. Lee E., Lobigs M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J. Virol. 2008, 82:6024-6033.
22. Levine M.M. "IDEAL" vaccines for resource poor settings. Vaccine 2011, 29(Suppl 4):D116-125.
23. Li G., Duan T., Wu X., Tesh R.B., Soong L., Xiao S.Y. Yellow fever virus infection in Syrian golden hamsters: relationship between cytokine expression and pathologic changes. Int. J. Clin. Exp. Pathol. 2008, 1:169-179.
24. Mantel N., Girerd Y., Geny C., Bernard I., Pontvianne J., Lang J., Barban V. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 2011, 29:6629-6635.
25. Meier K.C., Gardner C.L., Khoretonenko M.V., Klimstra W.B., Ryman K.D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 2009, 5:e1000614.
26. Messer W.B., Yount B., Hacker K.E., Donaldson E.F., Huynh J.P., de Silva A.M., Baric R.S. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl. Trop. Dis. 2012, 6:e1486.
27. Monath T.P. Yellow fever vaccine. Expert Rev. Vaccines 2005, 4:553-574.
28. Monath T.P., Brinker K.R., Chandler F.W., Kemp G.E., Cropp C.B. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am. J. Trop. Med. Hyg. 1981, 30:431-443.
29. Monath T.P., Fowler E., Johnson C.T., Balser J., Morin M.J., Sisti M., Trent D.W. An inactivated cell-culture vaccine against yellow fever. N. Engl. J. Med. 2011, 364:1326-1333.
30. Neves P.C., Matos D.C., Marcovistz R., Galler R. TLR expression and NK cell activation after human yellow fever vaccination. Vaccine 2009, 27:5543-5549.
31. Neves P.C., Santos J.R., Tubarao L.N., Bonaldo M.C., Galler R. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses. PLoS One 2013, 8:e81953.
32. Paessler S., Walker D.H. Pathogenesis of the viral hemorrhagic fevers. Annu. Rev. Pathol. 2013, 8:411-440.
33. Patel D., Simons H. Yellow fever vaccination: is one dose always enough?. Travel Med. Infect. Dis. 2013, 11:266-273.
34. Pugachev K.V., Guirakhoo F., Ocran S.W., Mitchell F., Parsons M., Penal C., Girakhoo S., Pougatcheva S.O., Arroyo J., Trent D.W., Monath T.P. High fidelity of yellow fever virus RNA polymerase. J. Virol. 2004, 78:1032-1038.
35. Pushko, P., Lukashevich, I., 2014. IDNA vaccines and methods for using the same U.S. Patent No. 8,691,563. Medigen, Inc., USA.
36. Quaresma J.A., Pagliari C., Medeiros D.B., Duarte M.I., Vasconcelos P.F. Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev. Med. Virol. 2013, 23:305-318.
37. Rafferty E., Duclos P., Yactayo S., Schuster M. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine 2013, 31:5798-5805.
38. Rice C.M., Grakoui A., Galler R., Chambers T.J. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol. 1989, 1:285-296.
39. Rutkowski K., Ewan P.W., Nasser S.M. Administration of yellow fever vaccine in patients with egg allergy. Int. Arch. Allergy Immunol. 2013, 161:274-278.
40. Schafer B., Holzer G.W., Joachimsthaler A., Coulibaly S., Schwendinger M., Crowe B.A., Kreil T.R., Barrett P.N., Falkner F.G. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS One 2011, 6:e24505.
41. Schlesinger J.J., Brandriss M.W., Cropp C.B., Monath T.P. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 1986, 60:1153-1155.
42. Staples J.E., Monath T.P. Yellow fever: 100 years of discovery. JAMA 2008, 300:960-962.
43. Stoyanov C.T., Boscardin S.B., Deroubaix S., Barba-Spaeth G., Franco D., Nussenzweig R.S., Nussenzweig M., Rice C.M. Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine 2010, 28:4644-4652.
44. Tesh R.B., Guzman H., da Rosa A.P., Vasconcelos P.F., Dias L.B., Bunnell J.E., Zhang H., Xiao S.Y. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J. Infect. Dis. 2001, 183:1431-1436.
45. Thibodeaux B.A., Garbino N.C., Liss N.M., Piper J., Blair C.D., Roehrig J.T. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine 2012, 30:3180-3187.
46. Tretyakova I., Hearn J., Wang E., Weaver S., Pushko P. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J. Infect. Dis. 2014.
47. Tretyakova I., Lukashevich I.S., Glass P., Wang E., Weaver S., Pushko P. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. Vaccine 2013, 31:1019-1025.
48. van der Heijden I., Beijnen J.H., Nuijen B. Long term stability of lyophilized plasmid DNA pDERMATT. Int. J. Pharm. 2013, 453:648-650.
49. Weaver S.C. Urbanization and geographic expansion of zoonotic arboviral diseases: mechanisms and potential strategies for prevention. Trends Microbiol. 2013, 21:360-363.
50. Woodson S.E., Freiberg A.N., Holbrook M.R. Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes. Virus Res. 2013, 175:155-159.